What Are Ipamorelin and CJC-1295? Differences, Evidence & FDA Status

PEPTIDE SCIENCE · EVIDENCE EXPLAINED

Two peptides. Different signals. Important unknowns.

Understanding the names, the studies and the limits of the evidence comes before any discussion of treatment.

Medically reviewed by Timothy Mackey, D.O.
Reviewed September 10, 2026

What is ipamorelin?

Ipamorelin is a synthetic growth hormone secretagogue—a substance that can prompt GH release. It activates the growth hormone secretagogue receptor, commonly called the ghrelin receptor. It is not testosterone and it does not directly replace growth hormone.

Human research has included an intravenous study for bowel recovery after surgery. That is a different question from whether a subcutaneous wellness regimen improves sleep, strength or body composition. The route, population and outcome all matter when interpreting a study.

What is CJC-1295?

CJC-1295 is a modified analog of growth-hormone-releasing hormone (GHRH). GHRH helps signal the pituitary gland to release GH. The long-acting CJC-1295 studied in early trials used a modification designed to bind albumin, a protein in blood.

The term is used inconsistently online. A study of one CJC-1295 form cannot establish the benefits, duration or safety of every product sold under that name.

How do they affect GH and IGF-1?

GH influences production of insulin-like growth factor 1 (IGF-1), including in the liver. This is a simplified explanation of a regulated system with feedback signals. More stimulation does not automatically mean better health.

A measured change in GH or IGF-1 can show that a substance has a biological effect. Demonstrating better function, fewer symptoms or improved long-term outcomes requires different evidence.

What do “with DAC” and “without DAC” mean?

DAC stands for drug affinity complex. The DAC modification enables albumin binding and is part of the long-acting molecule investigated in the best-known CJC-1295 human studies.

Products described as “without DAC” lack that modification. Online terminology may also include “modified GRF (1-29),” but a marketing name alone is not reliable confirmation of molecular identity or quality.

The FDA's CJC-1295 review distinguishes DAC and non-DAC substances and cautions against extrapolating their pharmacology. Do not apply a long-acting study's findings to a no-DAC product or assume that one version has been shown safer.

Why are ipamorelin and CJC-1295 discussed together?

The proposed rationale is complementary stimulation through two receptor pathways. That helps explain the interest in combining them; it does not demonstrate a clinically useful or safe combination.

A combination needs its own evidence. Results for a single substance, a different route or a different formulation cannot validate a blend. Nor does combining two unapproved substances create an approved medicine.

What does the human evidence actually show?

Why there is no reliable month-by-month results timeline

There is no validated schedule predicting better skin in one month, fat loss in another, or improved joints, hair, nails, libido or mental clarity by month six. The evidence does not support that level of certainty.

Testimonials cannot separate a peptide's effect from changes in diet, training, sleep, other medications or expectation. Even a real laboratory response does not establish that an advertised physical change will follow.

Are either FDA-approved?

No. Ipamorelin and CJC-1295 have no FDA-approved indication. Describing these substances simply as “off-label” can confuse matters: off-label use generally refers to a use of an approved drug outside its approved labeling.

Compounded drugs are not FDA-approved. A prescription, pharmacy license or certificate of analysis does not substitute for FDA review of a drug's safety and effectiveness.

What are the compounding issues?

Compounding status and drug approval are separate questions. Eligibility depends on the exact substance and applicable framework, not merely the word “peptide.” A committee discussion, nomination or removal from a list does not itself grant drug approval.

Status checked September 10, 2026: FDA's safety-risk page lists CJC-1295 and ipamorelin acetate among substances whose nominations were withdrawn; ipamorelin acetate also appears in Category 2 under the 503B interim policy. This is not a blanket statement that either can currently be supplied to a patient.

Current legal eligibility and any pharmacy availability require verification for the exact product. Online claims that all peptides have been “approved” or “unbanned” are not sufficient evidence.

What safety uncertainties matter?

FDA identifies impurity and immune-reaction concerns for these peptides. For CJC-1295 it reports increased heart rate and systemic vasodilatory reactions. For ipamorelin it cites serious events, including death, in an intravenous clinical setting and inadequate information about certain other injection routes. Those reports do not establish that ipamorelin caused every event or predict the risk of another route. Read FDA's safety discussion.

Unknown long-term risk is not the same as demonstrated safety. Changes in GH/IGF-1 signaling may be especially relevant when a person has a cancer history, glucose-control problems or an endocrine disorder. Such conditions require an appropriate clinical assessment; monitoring cannot make an inadequately studied product risk-free.

Do not inject material labeled “research use only.” A purity claim alone does not establish sterility or suitability for human use. Severe allergic symptoms, chest pain or difficulty breathing require urgent care.

Is a low IGF-1 level enough to justify treatment?

No. Adult growth hormone deficiency is a specific diagnosis. The Endocrine Society guideline generally calls for stimulation testing in an appropriate clinical context, with exceptions in defined circumstances. One low or low-normal IGF-1 result is not a prescription for these peptides.

Symptoms such as fatigue and poor recovery can have many causes. An assessment should determine what problem needs treatment rather than treating a hormone number as an anti-aging target.

What alternatives are worth discussing?

The appropriate alternative depends on the diagnosis. Suspected pituitary disease warrants endocrine evaluation. Confirmed growth hormone deficiency has established replacement options; that does not make prescription GH an appropriate wellness substitute.

For weight, sleep, sexual symptoms or persistent fatigue, discuss a focused evaluation and treatments supported for the identified condition. Another investigational peptide is not automatically a better answer. Our peptide education guide explains the broader context.

Frequently asked questions

Are ipamorelin and CJC-1295 the same thing?

No. They act through different receptors. The combined name describes two substances, not a single approved drug.

Are they HGH?

No. They are discussed as stimulators of GH release. Prescription growth hormone replaces the hormone itself.

Does a higher IGF-1 prove the treatment works?

It may demonstrate a biological response, but it does not prove improvement in a symptom, body composition or long-term health.

Is no-DAC CJC-1295 safer?

That conclusion is not established. Different molecular forms have different properties, and limited data do not permit a blanket safety ranking.

How long until I see results?

There is no evidence-based wellness-results timeline for this combination. Published hormone changes should not be converted into promised physical outcomes.

Is there an FDA-approved dose for the combination?

No. There is no approved combination regimen for these substances. This article does not provide a dosing or self-injection protocol.

Educational information. Evidence and regulatory sources checked September 10, 2026.